Tumor necrosis factor‑α‑induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells

Zhu,Li Bing; Zhao,Sheng Tao; Xu,Ting Zhao; Wang,He

doi:10.3892/ol.2014.1810

2014-March Volume 7 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

2014-March Volume 7 Issue 3

Full Size Image

Article

Tumor necrosis factor‑α‑induced a disintegrin and metalloprotease 10 increases apoptosis resistance in prostate cancer cells

Authors:
- Li Bing Zhu
- Sheng Tao Zhao
- Ting Zhao Xu
- He Wang
View Affiliations / Copyright

Affiliations: Department of Urology, The People's Liberation Army Mount Lu Sanatorium, Jiujiang, Jiangxi 332000, P.R. China, Department of Respiratory Medicine, Kunming General Hospital of Chengdu Military Area Command, Kunming, Yunnan 650000, P.R. China, Department of Urology, Fuzhou General Hospital of Nanjing Military Area Command, Fuzhou, Fujian 350000, P.R. China, Department of Urology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Pages: 897-901
|
Published online on: January 16, 2014

https://doi.org/10.3892/ol.2014.1810
Expand metrics +

Abstract

In developed countries, prostate cancer (PCa) is the second most frequently diagnosed type of cancer and the third most common cause of cancer‑related mortality in males. Compared with western countries, the morbidity rate of PCa in China is markedly lower, however, it is rising annually. The etiology of PCa is unclear, therefore, to investigate how a disintegrin and metalloprotease 10 (ADAM10) functions in PCa, ADAM10 mRNA and protein levels induced by tumor necrosis factor (TNF)‑α were identified using polymerase chain reaction and flow cytometry, respectively. To investigate the mechanism of ADAM10 activity in PCa, specific inhibitors were used, and DNA transfection and RNA interference technology were employed to identify the interaction between ADAM10 and the Fas ligand (L). The results indicated that TNF‑α induced ADAM10 expression in a time‑ and dose‑dependent manner through the p38 mitogen‑activated protein kinase/necrosis factor‑κB signaling pathway. ADAM10 hydrolyzed FasL and contributed to apoptosis resistance of the tumor cells. These observations indicate a promising therapeutic modality for the treatment of apoptosis‑resistant PCa, by targeting ADAM10 sheddase activity.

View Figures

View References

1	Fox JJ, Schöder H and Larson SM: Molecular imaging of prostate cancer. Curr Opin Urol. 22:320–327. 2012. View Article : Google Scholar
2	Ouyang DY, Xu LH, He XH, et al: Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy. 9:20–32. 2013. View Article : Google Scholar
3	Hao Y, Zhao Y, Zhao X, et al: Improvement of prostate cancer detection by integrating the PSA test with miRNA expression profiling. Cancer Invest. 29:318–324. 2011. View Article : Google Scholar : PubMed/NCBI
4	Damber JE and Aus G: Prostate cancer. Lancet. 371:1710–1721. 2008. View Article : Google Scholar : PubMed/NCBI
5	Eastham JA, May RA, Whatley T, Crow A, Venable DD and Sartor O: Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. J Natl Cancer Instit. 90:756–760. 1998. View Article : Google Scholar : PubMed/NCBI
6	Mononen N and Schleutker J: Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol. 181:1541–1549. 2009. View Article : Google Scholar : PubMed/NCBI
7	Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer: new molecular links. Ann NY Acad Sci. 1155:206–221. 2009. View Article : Google Scholar : PubMed/NCBI
8	Coyle YM: Lifestyle, genes, and cancer. Methods Mol Biol. 472:25–56. 2009. View Article : Google Scholar : PubMed/NCBI
9	Wu H, Haag D, Muley T, et al: Tumor-microenvironment interactions studied by zonal transcriptional profiling of squamous cell lung carcinoma. Genes Chromosomes Cancer. 52:250–264. 2013. View Article : Google Scholar
10	Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature. 411:375–379. 2001. View Article : Google Scholar : PubMed/NCBI
11	López-Otín C and Matrisian LM: Emerging roles of proteases in tumour suppression. Nat Rev Cancer. 7:800–808. 2007.PubMed/NCBI
12	Hua H, Li M, Luo T, Yin Y and Jiang Y: Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 68:3853–3868. 2011. View Article : Google Scholar : PubMed/NCBI
13	Orlichenko LS and Radisky DC: Matrix metalloproteinases stimulate epithelial-mesenchymal transition during tumor development. Clin Exp Metastasis. 25:593–600. 2008. View Article : Google Scholar
14	Mochizuki S and Okada Y: ADAMs in cancer cell proliferation and progression. Cancer Sci. 98:621–628. 2007. View Article : Google Scholar : PubMed/NCBI
15	Rocks N, Paulissen G, El Hour M, et al: Emerging roles of ADAM and ADAMTS metalloproteinases in cancer. Biochimie. 90:369–379. 2008. View Article : Google Scholar : PubMed/NCBI
16	Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med. 29:258–289. 2008. View Article : Google Scholar
17	Seals DF and Courtneidge SA: The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar
18	Grabowska MM, Sandhu B and Day ML: EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal. 24:532–538. 2012. View Article : Google Scholar : PubMed/NCBI
19	Maretzky T, Scholz F, Köten B, Proksch E, Saftig P and Reiss K: ADAM10-mediated E-cadherin release is regulated by proinflammatory cytokines and modulates keratinocyte cohesion in eczematous dermatitis. J Invest Dermatol. 128:1737–1746. 2008. View Article : Google Scholar
20	Schirrmeister W, Gnad T, Wex T, et al: Ectodomain shedding of E-cadherin and c-Met is induced by Helicobacter pylori infection. Exp Cell Res. 315:3500–3508. 2009. View Article : Google Scholar : PubMed/NCBI
21	Arima T, Enokida H, Kubo H, et al: Nuclear translocation of ADAM-10 contributes to the pathogenesis and progression of human prostate cancer. Cancer Science. 98:1720–1726. 2007. View Article : Google Scholar
22	Liu WH and Chang LS: Piceatannol induces Fas and FasL up-regulation in human leukemia U937 cells via Ca²⁺/p38alpha MAPK-mediated activation of c-Jun and ATF-2 pathways. Int J Biochem Cell Biol. 42:1498–1506. 2010. View Article : Google Scholar : PubMed/NCBI
23	McCulloch DR, Akl P, Samaratunga H, Herington AC and Odorico DM: Expression of the disintegrin metalloprotease, ADAM-10, in prostate cancer and its regulation by dihydrotestosterone, insulin-like growth factor I, and epidermal growth factor in the prostate cancer cell model LNCaP. Clin Cancer Res. 10:314–323. 2004. View Article : Google Scholar
24	Blobel CP: ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 6:32–43. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lamour NF, Wijesinghe DS, Mietla JA, Ward KE, Stahelin RV and Chalfant CE: Ceramide kinase regulates the production of tumor necrosis factor alpha (TNFalpha) via inhibition of TNFα-converting enzyme. J Biol Chem. 286:42808–42817. 2011.
26	Szlosarek PW and Balkwill FR: Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 4:565–573. 2003. View Article : Google Scholar : PubMed/NCBI
27	Cuadrado A and Nebreda AR: Mechanisms and functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010. View Article : Google Scholar : PubMed/NCBI
28	Cargnello M and Roux PP: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
29	Chung KF: p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 139:1470–1479. 2011. View Article : Google Scholar : PubMed/NCBI
30	Karin M: Nuclear factor-kappaB in cancer development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
31	Bhoj VG and Chen ZJ: Ubiquitylation in innate and adaptive immunity. Nature. 458:430–437. 2009. View Article : Google Scholar : PubMed/NCBI
32	Karin M and Greten FR: NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol. 5:749–759. 2005. View Article : Google Scholar : PubMed/NCBI
33	Strasser A, Jost PJ and Nagata S: The many roles of FAS receptor signaling in the immune system. Immunity. 30:180–192. 2009. View Article : Google Scholar : PubMed/NCBI
34	Krammer PH: CD95’s deadly mission in the immune system. Nature. 407:789–795. 2000.
35	Villa-Morales M and Fernández-Piqueras J: Targeting the Fas/FasL signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:85–101. 2012. View Article : Google Scholar : PubMed/NCBI
36	Liu WH and Chang LS: Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol. 43:1708–1719. 2011. View Article : Google Scholar